Compare

Cagrilintide vs CBL-514

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Cagrilintide

1559 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 53% · Mixed 28% · Unfavorable overall 19%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
-38
Appetite control
5
Energy
-34
Mood
-17
Focus
-127

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
-122
GI discomfort
-95
Dizziness
-69
Fatigue
-21
Nausea
-128

Self-reported dose per injection

Median bucket: 0.6–1 mg · Most common: 0.6–1 mg

Reports span 0.05 to ≥ 5 mg (open-ended top bucket)

0.05–0.1 mg
4
0.1–0.2 mg
7
0.2–0.4 mg
12
0.4–0.6 mg
18
0.6–1 mg
29
1–2 mg
24
2–3 mg
13
3–5 mg
4
5+ mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing43stacking21side effects19cagrilintide17

How repeat users are trending

Among repeat reporters, 63% said they felt similar to their last entry, 39% more positive, and 13% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 25 days · Based on 343 repeat reporters

CBL-514

1416 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 60% · Mixed 32% · Unfavorable overall 8%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Digestive comfort
91
Skin appearance
111
Appetite control
136
Energy
95
Mood
44

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Flushing
187
Headache
191
GI discomfort
101
Dizziness
90
Fatigue
44

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 0–1000 mcg

0–10
2
10–25
6
25–50
11
50–100
17
100–200
28
200–400
19
400–600
11
600–1000
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing20stacking38side effects26cbl-51424

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 34% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 14 days · Based on 312 repeat reporters

Sources (16)

Published sources linked on the Cagrilintide and CBL-514 wiki pages.

  1. PubMed

    Cagrilintide, a long-acting amylin analogue, for the treatment of obesity

    Lau DCW, Erondu N, Skovgaard D, et al. Lancet. 2022

    Source
    Wiki study page →
  2. ClinicalTrials.gov

    Cagrilintide obesity studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  3. PubMed

    Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity

    D'Ascanio AM, Mullally JA, Frishman WH. Cardiology in review. 2024

    Source
    Wiki study page →
  4. PubMed

    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

    Garvey WT, Blüher M, Osorto Contreras CK, et al. The New England journal of medicine. 2025

    Source
    Wiki study page →
  5. PubMed

    Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study

    Gold M, Schlessinger J, Goodman GJ, et al. Aesthetic Surgery Journal. 2025

    Source
    Wiki study page →
  6. PubMed

    Randomized Phase 2b Trial of CBL-514 Injection for Abdominal Subcutaneous Fat Reduction With Clinician- and Patient-reported Outcomes and MRI Assessment

    Lorenc ZP, Gold M, Schlessinger J, et al. Aesthetic Surgery Journal. 2026

    Source
    Wiki study page →
  7. PubMed

    Efficacy of a Novel Injection Lipolysis to Induce Targeted Adipocyte Apoptosis: A Randomized, Phase IIa Study of CBL-514 Injection on Abdominal Subcutaneous Fat Reduction

    Goodman GJ, Ho WWS, Chang KJ, et al. Aesthetic Surgery Journal. 2022

    Source
    Wiki study page →
  8. PubMed

    Efficacy and safety of CBL-514 for Dercum disease lipomas: A randomized phase 2a study

    Herbst KL, Ling YF, Sheu AY, et al. JAAD International. 2026

    Source
    Wiki study page →
  9. ClinicalTrials.gov

    SUPREME-01 (NCT07140939): Phase 3 CBL-514 for abdominal subcutaneous fat

    ClinicalTrials.gov. Clinical trial registry. 2026

    Source
    Wiki study page →
  10. ClinicalTrials.gov

    SUPREME-02 (NCT07526974): Phase 3 CBL-514 for abdominal subcutaneous fat

    ClinicalTrials.gov. Clinical trial registry. 2026

    Source
    Wiki study page →
  11. Manufacturer

    Caliway Announces First Patient Dosed in Global Phase 3 SUPREME-01 Trial of CBL-514

    Caliway Biopharmaceuticals. Company press release. 2026

    Source
    Wiki study page →
  12. Manufacturer

    Caliway Highlights Global Phase 3 Progress and GLP-1 Combination Strategy (Aug 31, 2026 Investor Conference)

    Caliway Biopharmaceuticals. Company press release. 2026

    Source
    Wiki study page →
  13. Manufacturer

    Caliway Completes U.S. FDA IND Submission for SUPREME-02 Phase 3 Study of CBL-514

    Caliway Biopharmaceuticals. Company press release. 2026

    Source
    Wiki study page →
  14. FDA Drug Label

    KYBELLA (deoxycholic acid) injection — Prescribing Information

    Allergan. FDA Drug Label. 2015

    Source
    Wiki study page →
  15. Review Article

    An experimental drug kills fat cells, rather than shrinking them

    Tina Hesman Saey, Science News. Science News. 2026

    Source
    Wiki study page →
  16. Review Article

    CBL-514 injection reduces visceral and subcutaneous fat in trials

    News-Medical.net. Conference news summary. 2026

    Source
    Wiki study page →